

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **BUDESONIDE ENTERIC-COATED CAPSULES OBTAIN DRUG REGISTRATION APPROVAL**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that budesonide enteric-coated capsules (4mg) (the “**Product**”) developed by the Group have obtained drug registration approval granted by the National Medical Products Administration (NMPA) of the People’s Republic of China.

Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity, and undergoes extensive first-pass metabolism. Budesonide can inhibit the proliferation of mucosal B cells and their differentiation into plasma cells in the Peyer’s patches of the ileum, thereby suppressing the production of galactose-deficient IgA1 antibodies (“**Gd-IgA1**”). By reducing the formation of Gd-IgA1 antibodies and immune complexes in the systemic circulation, it reduces the deposition of immune complexes in the glomerular mesangial region which leads to glomerulonephritis and renal function decline. The Product is indicated for the treatment of adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression to reduce the loss of renal function. Compared with other drugs, the Product is a pathogenesis-targeted treatment for IgA nephropathy. It adopts a dual delayed-release and sustained-release formulation technology to achieve targeted treatment, with low systemic exposure and a high safety profile.

The approval of the Product will further enrich the Group’s product portfolio in the nephrology therapeutic area and enhance the Group’s competitiveness in this field.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 21 May 2026

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*